Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up
28th May 2025 Uncategorised 0A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme, the developer of the treatment, Scynexis, has resumed a phase 3 study, dosing its first new patient. The trial resumption triggers a $10 million milestone payment from GSK and another $20 million due in six months, Scynexis says, with the British pharma giant disputing the charges.
More: Scynexis says GSK on hook for M payment after phase 3 Brexafemme trial starts back up
Source: fierce